NO20050436L - Beta-layer-breaking peptides - Google Patents

Beta-layer-breaking peptides

Info

Publication number
NO20050436L
NO20050436L NO20050436A NO20050436A NO20050436L NO 20050436 L NO20050436 L NO 20050436L NO 20050436 A NO20050436 A NO 20050436A NO 20050436 A NO20050436 A NO 20050436A NO 20050436 L NO20050436 L NO 20050436L
Authority
NO
Norway
Prior art keywords
layer
beta
peptides
breaking
breaking peptides
Prior art date
Application number
NO20050436A
Other languages
Norwegian (no)
Other versions
NO20050436D0 (en
Inventor
Celine Adessi
Serge Halazy
Claudio Soto-Jara
Thomas Rueckle
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20050436D0 publication Critical patent/NO20050436D0/en
Publication of NO20050436L publication Critical patent/NO20050436L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er tilveiebrakt peptider som har lagnedbrytende evne, som er nyttige til behandling og forhindring av sykdommer så som Alzheimers sykdom. Dementia pugilistica (inkludert hodetraume), arvelig cerebral blødning med amyloidose av den hollandske typen (HeHWA-D) og vaskulær demens med amyloid angiopati.There are peptides that have layer-breaking ability, which are useful for treating and preventing diseases such as Alzheimer's disease. Dementia pugilistica (including head trauma), hereditary cerebral haemorrhage with amyloidosis of the Dutch type (HeHWA-D) and vascular dementia with amyloid angiopathy.

NO20050436A 2002-07-08 2005-01-26 Beta-layer-breaking peptides NO20050436L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02100787 2002-07-08
EP02102834 2002-12-19
PCT/EP2003/050287 WO2004005336A2 (en) 2002-07-08 2003-07-07 β-SHEET BREAKING PEPTIDES

Publications (2)

Publication Number Publication Date
NO20050436D0 NO20050436D0 (en) 2005-01-26
NO20050436L true NO20050436L (en) 2005-01-26

Family

ID=30116915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050436A NO20050436L (en) 2002-07-08 2005-01-26 Beta-layer-breaking peptides

Country Status (7)

Country Link
EP (1) EP1532170A2 (en)
JP (1) JP2006508904A (en)
AU (1) AU2003271745A1 (en)
CA (1) CA2489754A1 (en)
IL (1) IL166102A0 (en)
NO (1) NO20050436L (en)
WO (1) WO2004005336A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065042A1 (en) 2011-03-11 2013-03-14 The Board Of Trustees Of The University Of Illinois Micro-Vascular Materials And Composites For Forming The Materials
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917724D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Also Published As

Publication number Publication date
JP2006508904A (en) 2006-03-16
CA2489754A1 (en) 2004-01-15
EP1532170A2 (en) 2005-05-25
NO20050436D0 (en) 2005-01-26
WO2004005336A2 (en) 2004-01-15
WO2004005336A3 (en) 2004-02-26
AU2003271745A1 (en) 2004-01-23
IL166102A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
NO20052223L (en) Thiazole compounds for the treatment of neurodegenerative disorders
DK2527315T3 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
NO961326D0 (en) Inhibitors of
NO992463L (en) N- (aryl / heteroarylacetyl) amino acid esters, pharmaceutical compositions including the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds
NO20064726L (en) Imidazole compounds for the treatment of neurodegenerative disorders
NO20053855L (en) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
NO20060768L (en) 1- (2-Amino-benzene) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
DE60219917D1 (en) NAPHTOQUINONE DERIVATIVES AS INHIBITORS OF TAU AGGREGATION FOR THE TREATMENT OF ALZHEIMER'S AND ASSOCIATED NEURODEEGENERATIVE DISEASES
DK1567488T3 (en) Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
NO20060541L (en) Pinerazine with OR-substituted phenyl grounds and their use as GlyT1 inhibitors
WO2004080376A3 (en) Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
NO20064989L (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
DK2172208T3 (en) Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
ATE357438T1 (en) 1,2,4-TRIAMINOBENZENE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
NO20055309D0 (en) Slurp-1 coagulation schemes and methods for using them
NO20053237L (en) Azapeptide.
NO20053341D0 (en) Prevention and treatment of Alzheimer's disease.
NO20055668L (en) Beta-amyloid inhibitors and their use
NO20070665L (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
NO20050436L (en) Beta-layer-breaking peptides
WO2004066940A3 (en) Compositions and methods containing substituted quinolines and substituted diphenylsulfones
NO20065196L (en) Therapeutic combination for the treatment of Alzheimer's disease
NO20074562L (en) Procedures for the treatment of Parkinson's disease
DK0707477T3 (en) Use of Efaxoran and its derivatives in the manufacture of drugs intended to treat neurodegenerative diseases

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application